



INFORMATION DISCLOSURE STATEMENT

Applicant: Goddard, et al. (as amended)

App. No. : 10/063,534

Filed : May 2, 2002

For : ANTIBODIES TO A POLYPEPTIDE
ENCODED BY A NUCLEIC ACID
OVEREXPRESSED IN KIDNEY
TUMOR AND UNDEREXPRESSED
IN LUNG TUMOR

Examiner : Seharaseyon, J.

Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 17, 2005

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 28 references to be considered by the Examiner. Also enclosed are 15 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

Please place these references in the file of the above-identified patent application in accordance with 37 C.F.R. § 1.97(i).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

Dated:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>		Application No.	10/063,534
		Filing Date	May 2, 2002
		First Named Inventor	Goddard, et al. (as amended)
		Art Unit	1647
SHEET 1 OF 2		Examiner	Seharaseyon, J.
		Attorney Docket No.	GNE.3230R1C23

MAR 21 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582	05-08-2001	Rodier, et al.	
	6	6,395,306	05-28-2002	Cui, et al.	
	7	6,414,117	07-02-2002	Levinson, D. A.	
	8	6,465,185	10-15-2002	Goldfine, et al.	
	9	6,498,235	12-24-2002	Sheppard, et al.	
	10	6,562,343	05-13-2003	Levinson, D. A.	
	11	6,645,499	11-11-2003	Lal, et al.	
	12	6,730,502	05-04-2004	Van Hijum, et al.	
	13	6,737,522	05-18-2004	Sundick, et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	16	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	17	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. <i>Molecular and Cellular Biology</i> , 1720-1730.	
	18	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	19	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. <i>Cancer Research</i> , 62:6240-6245.	
	20	LEWIN, B. 1994. <i>Oncogenes: Gene Expression and Cancer</i> , Chap. 39, pp.1196-1201. <i>Genes V</i> . New York: Oxford University Press.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/063,534
		Filing Date	May 2, 2002
		First Named Inventor	Goddard, et al. (as amended)
		Art Unit	1647
(Multiple sheets used when necessary)		Examiner	Seharaseyon, J.
SHEET 2 OF 2		Attorney Docket No.	GNE.3230R1C23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Citation No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	21	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	22	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	23	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	24	New England Biolabs catalog 2002-2003. Page 122.	
	25	ORNTOFF et al. 2001. Genome-wide Study of Gene Copy Numbers -Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carcinomas. <i>Molecular and Cellular Proteomics</i> 1.1:39.	
	26	POLLACK et al. Oct 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of breast tumors. <i>PNAS</i> 99(20).	
	27	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	
	28	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1349316_1
031705

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.